ALK and neuroblastoma: This study confirmed that elimusertib or ceralasertib, which leads to a highly similar reduction of ATR and mTOR signaling, may be driven by a compensatory activation response of both ATM and DNAPK, thus showing a clue that combination therapeutic strategy based on ATR inhibitor for the treatment of ALK-positive NB patients.